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Aim 1: To examine the efficacy of antidepressant agents compared with placebo in reducing 
depressive symptoms in subjects with comorbid Alcohol Use Disorders (AUD). 
Aim 2: To examine the efficacy of antidepressant agents compared with placebo on measures 
of alcohol consumption.   
Data Sources:  
Aim 1: PubMed was searched for randomized, placebo-controlled trials that examined the 
efficacy of antidepressant medications for treating depression symptoms with comorbid 
AUD. 
Aim 2: Ovid MEDLINE (1946 to September 23, 2016) and CENTRAL (Issue 8, August 
2016) were searched with no language limits for randomized placebo-controlled trials that 
examined the effects of antidepressant medications on alcohol consumption. 
Study Selection:  
Aim 1: Trials were included if they: 1) were randomized, placebo-controlled clinical trials, 2) 
examined the effects of an antidepressant medication for comorbid MDD and AUD, and 3) 
reported depression outcomes. 
Aim 2: Trials were included if they: 1) were randomized, placebo-controlled clinical trials, 2) 
examined the effects of an antidepressant medication for comorbid MDD and AUD, and 3) 
reported alcohol consumption outcomes. 
Data Extraction:  
Aim 1: Random effects meta-analysis was utilized to examine standardized mean difference 
(SMD) in improvement of depressive symptoms and risk ratio for treatment response. 
Stratified subgroup analysis was used to examine the moderating effects of type of 
antidepressant medication and other trial characteristics. 
Aim 2: We examined the effect of antidepressant treatment on four alcohol consumption 
outcomes: (1) drinking days, (2) drinks per day, (3) hazardous drinking days, and (4) 
abstinence rates. Our primary outcome was standardized mean difference for continuous 
measures and risk ratio for dichotomous outcomes using random effects meta-analysis. We 
also used stratified subgroup analysis to examine the moderating effects of type of 
antidepressant medication and diagnostic indication. 
Results:  
Aim 1: Eighteen distinct trial arms involving 1,318 participants were included in this 
systematic review and meta-analysis. In subjects with AUD, antidepressant medications 
significantly decreased depression severity compared with placebo (SMD=0.33±0.10 (95% 
Confidence Interval (CI): 0.14-0.51, k=18, z=3.4, p=0.001). Type of antidepressant 
medication did not significantly affect the magnitude of depressive symptom improvement 
compared with placebo (Test for subgroup differences χ2=2.15, df=2, p=0.34). TCAs 
(SMD=0.51±0.19 (95% CI: 0.15-0.88, k=3, z=2.7, p=0.006) and SSRIs (SMD=0.22±0.12 
(95% CI: -0.01-0.46, k=10, z=1.9, p=0.06) suggested similar benefits for depressive 
symptoms in subjects with comorbid AUD. The use of concomitant psychotherapy (for either 
depression or alcohol use) (Test for subgroup differences χ2=9.9, df=1, p=0.002) or 
concomitant pharmacotherapy for AUD (Test for subgroup differences χ2=4.7, df=1, p=0.03) 
was associated with a significantly smaller measured treatment benefit of antidepressant 
agents. 
Aim 2: Twenty-six trials involving 2,771 participants were included in this systematic review 
and meta-analysis. Overall, antidepressant use was not associated with significant changes in 
drinking outcomes (drinking days, drinks per day, abstinence rates, and hazardous drinking 
days). When antidepressants were utilized to treat comorbid depression symptoms, 
antidepressant treatment was associated with improved drinking outcomes on some (drinking 
days and drinks per day) but not all measures (abstinence rates and hazardous drinking days). 
When antidepressants were utilized primarily to treat symptoms of other disorders, 
antidepressant treatment was associated with worsened drinking outcomes on some (drinking 
days and drinks per day) but not all measures (abstinence rates and hazardous drinking days). 
Class of antidepressant treatment did not significantly affect any drinking-related outcomes. 
Conclusion:  
Aim 1: Our meta-analysis suggests that antidepressant medications significantly decrease 
depressive symptoms in participants with comorbid AUD. The magnitude of depressive 
symptom improvement in subjects with comorbid AUD appears similar to that achieved in 
MDD trials without comorbid substance use. 
Aim 2: Antidepressant therapy results in improvement in some drinking outcomes when used 
for comorbid depression, though it may worsen these outcomes in the absence of comorbid 
depression. More research is needed on the impact of antidepressants on drinking outcomes, 













Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD) are among the 
most prevalent mental health conditions in adult populations. AUD is overrepresented in 
adults with MDD compared with the general population, and depression is overrepresented in 
patients with AUD.1 Recent genetic analysis supports a strong genetic overlap between MDD 
and AUD.2 Patients with MDD and comorbid AUD tend to experience greater depression 
severity, depressive symptoms at an earlier age of onset, increased suicidality and functional 
impairment, higher rates of relapse and decreased likelihood of recovery from depressive 
symptoms.3-7 In patients with AUD, comorbid depressive symptoms are associated with an 
increased likelihood of treatment dropout and relapse.8-10 
Pharmacotherapy with antidepressant medications is a first-line treatment for MDD. 
In meta-analysis, antidepressant agents demonstrate a significant benefit compared with 
placebo for the treatment of major depression with effect sizes of 0.3011 and 0.3712 reported 
in the literature and a NNT of 6.13 Despite the high rate of comorbidity between AUD and 
MDD, subjects who meet criteria for current or recent alcohol or other substance use 
disorders are typically excluded from these pivotal randomized, placebo-controlled trials of 
antidepressant medications. Thus, it is uncertain how well the results of positive 
antidepressant trials in non-alcohol dependent patients will generalize to clinical MDD 
populations, where patients often have comorbid AUD.14-20 
Previous meta-analyses have found mixed results regarding the efficacy of 
antidepressants in treating comorbid MDD and AUD. A 2004 meta-analysis found that 
antidepressants have a “modest beneficial effect” in reducing depressive symptoms in 
patients with a comorbid substance use disorder (not limited to AUD).21 A subsequent meta-
analysis suggested a similar effect when meta-analysis was confined to just trials involving 
subjects with comorbid AUD and MDD. This meta-analysis further reported that Selective 
Serotonin Reuptake Inhibitors (SSRIs), as a class, were not associated with an increased 
likelihood of response in terms of depressive symptoms, compared to placebo.22  
A more recent meta-analysis published in 2011 that similarly examined only 
treatment response, demonstrated that antidepressant agents overall were more effective than 
placebo at reducing depressive symptoms in patients with comorbid AUD. However, this 
meta-analysis was not able to demonstrate that SSRIs, as a class, were effective in this 
population and further suggested that they were less effective than other antidepressants.13 
These previous meta-analyses examined only treatment response and not continuous 
outcomes. Also, there are additional recent trials with second generation antidepressants that 
have been published subsequent to these previous reviews. 
Alcohol use disorder has a lifetime prevalence of 30.3% in the United States 
according to results from the National Epidemiologic Survey on Alcohol and Related 
Conditions (NESARC).23 Comorbid alcohol dependence and depression result in 44% more 
healthcare costs compared to treating depression alone.24 It has been suggested that alcohol 
use disorder may be causally linked to increased rates of depression,25 though genetic 
variations in serotonin transporter (SERT) function have also been implicated in both 
disorders.26 While second- and third-generation antidepressant medications remain the 
mainstay for treating depression,27 they can also be used in many other psychiatric conditions 
that are often comorbid with alcohol use disorder. For example, Americans with alcohol 
dependence are three times more likely to have an anxiety disorder and more than five times 
more likely to have nicotine dependence.23 Moreover, antidepressants were at one time the 
most commonly prescribed medication for alcohol use disorder,28 though several reviews and 
meta-analyses have questioned their efficacy for this indication.22, 29, 30 Unfortunately, there 
has been some case report31 and clinical trial32-35 evidence that the SSRI antidepressants may 
actually increase alcohol consumption in a subset of the population. This would suggest that 
providers should consider a different class of antidepressants for patients prone to alcohol use 
disorder. Of course, this assumes that classes of antidepressants other than SSRIs have 
superior outcomes. 
Two recent meta-analyses demonstrated the efficacy of antidepressants for treating 
depressive disorders in patients with comorbid alcohol use disorder, but either did not report36 
or reported only very limited data13 on alcohol consumption outcomes. Notably, a 2004 meta-
analysis21 studied antidepressant effects on both depression and substance use outcomes in 
the treatment of depressive disorders with comorbid dependence on alcohol or illicit drugs, 
and demonstrated improvement in substance use outcomes in the subset of studies in which 
depressive symptoms improved. Similarly, a 2005 meta-analysis22 examined alcohol and 
illicit drug outcomes in both studies of comorbid depression and studies without comorbid 
depression, but only found a statistically significant effect on substance use outcomes for 
first-generation antidepressants, in the treatment of comorbid depression and alcohol use 
disorder. 
 
Statement of Purpose 
The goals of the current meta-analyses are to update previous meta-analyses, as well 
as, to examine several unanswered questions regarding the use of antidepressant agents in 
subjects with MDD and comorbid AUD. In Aim 1, we specifically sought to determine: (1) 
What is the measured effect size and relative risk of response for subjects with MDD and AUD 
treated with antidepressant agents compared with placebo?; (2) Do different medication classes 
(TCA vs. SSRI) have the same measured benefit compared with placebo for subjects with 
MDD and AUD?; (3) Does the use of concomitant psychotherapy, targeting either depression 
or alcohol use, or concomitant pharmacotherapy for AUD moderate the benefits of 
antidepressant agents in the treatment of MDD with comorbid AUD?; and (4) Does the 
measured efficacy of antidepressant agents differ in trials where antidepressants are initiated 
before or after alcohol detoxification is completed?  
The systematic review and meta-analysis conducted as part of Aim 2 has the goal of 
updating and expanding upon previous studies by systematically analyzing trials that study 
the effects of second- and third-generation antidepressants on alcohol consumption outcomes, 
regardless of indication for the medication. This aim attempts to better delineate the effects of 
different antidepressant medication classes, specifically on alcohol consumption. 
 
Author Contributions 
IJ’s role in Aim 1 was in writing the manuscript, conceptual planning, identifying 
articles for quantitative synthesis (meta-analysis) through assessment of articles by title, 
abstract, and full-text based on inclusion and exclusion criteria, extraction and organization of 
the data from each included article, creation of Table 1 and Figure 1, conducting a review of 
the literature, and reviewing previous systematic reviews in this area. IJ’s role in Aim 2 was 
in writing and organizing sections of the manuscript and conducting a review of the literature. 
MHB supervised the conceptual planning and execution of both Aim 1 and Aim 2. He 
also wrote and organized sections of both manuscripts and performed the statistical analyses. 
JD’s role in Aim 2 was in writing the manuscript, conceptual planning, identifying 
articles for quantitative synthesis (meta-analysis) through assessment of articles by title, 
abstract, and full-text based on inclusion and exclusion criteria, extraction and organization of 
data, conducting a review of the literature, and reviewing previous systematic reviews in this 
area.  
MN reviewed the manuscript for Aim 1 and BA reviewed the manuscript for Aim 2. 
FL created all forest and funnel plot figures for both manuscripts. BS, JJ, and MM 
contributed to writing sections of the manuscript. BS created Table 2 for Aim 1. 
Aim 1: Effect of Antidepressants on Depression Outcomes 
Methods: 
Literature Search 
We aimed to identify all randomized, placebo-controlled clinical trials of 
antidepressants indicated for the treatment of either MDD or chronic dysthymic disorder in 
participants with comorbid alcohol use disorder, that reported depression outcomes. PubMed 
MEDLINE (1946 to 12/18/2017) was searched using the search strategy “Alcohol-Related 
Disorders"[Mesh] AND "Depressive Disorder"[Mesh]) AND ("Antidepressive 
Agents"[Mesh] OR "Antidepressive Agents"[Pharmacological Action]).” We further limited 
the search using the clinical trials filter. There were no language limitations on the search. 
We additionally examined the references of included trials and previous systematic reviews 
in the area to identify additional citations.13, 21, 22, 37 
 
Study Selection 
Following the removal of duplicate citations, abstracts were independently screened 
by two authors (IJ and BS) for full text review, according to the following inclusion criteria: 
1) randomized, placebo-controlled clinical trial, 2) utilization of an antidepressant medication 
to treat patients with AUD comorbid with either MDD or chronic dysthymic disorder, and 3) 
trials where depression outcomes were reported. Following this screening, full text articles 
were then reviewed by the same two authors according to the same inclusion criteria. 
Disagreements in both screening and full text review phases were resolved by consensus 
agreement in consultation with a senior reviewer (MHB). We excluded articles conducted in 
adolescents and articles that included patients who did not meet criteria for a current 
diagnosis of MDD or dysthymia. We included studies with concomitant use of naltrexone in 
the treatment and placebo arms despite evidence in previous literature of the confounding 
effects of this medication on alcohol consumption outcomes.38 This is due to the fact that the 
present study focused exclusively on depression-related outcomes, and we conducted a 




Custom designed Microsoft Excel spreadsheets were used to extract data. Data 
extracted from the identified trials included: bibliographic information; indication for the 
trial; antidepressant medication studied; maximum medication dose; duration of study; age 
and gender of subjects; number of participants (n) in intention-to-treat sample and number 
completing the trial; concomitant psychotherapeutic interventions and whether the 
psychotherapy specifically targeted depression or alcohol use; concomitant 
psychopharmacological interventions targeting alcohol use; and whether or not participants 
were required to stop drinking prior to the start of the study. The primary outcomes extracted 
for the meta-analysis included endpoint depressive symptom ratings and response in terms of 
depressive symptoms, for both active and placebo arms of each study. If trial outcomes were 
only reported in graphical form, a graph digitizer program called GetData39 was used to 
extract the data. When no aggregate data was available, studies that reported data of multiple 




Statistical analysis was performed using Comprehensive Meta-Analysis (version 
3.0).40 Given the variation of depression rating scales reported in the included studies, 
standardized mean difference was chosen as the summary statistic. For treatment response, a 
dichotomous outcome, risk ratio was utilized as the summary statistic. Given the 
heterogeneity in medications, trial design, and study outcomes, we chose to use a random-
effects model. Heterogeneity was assessed by calculating the Q statistic,41 and the I2. I2 is a 
transformation of the Q statistic that indicates the proportion of observed variance that can be 
attributed to heterogeneity rather than sampling error.42 Publication bias was assessed by 
creating funnel plots for the outcome measures by plotting the effect size against standard 
error for each included trial. In addition, publication bias was statistically tested by the Egger 
test.43 We conducted stratified subgroup analyses to examine the effects of type of 
antidepressant medication (SSRI, TCA, vs. other), whether concomitant psychotherapy was 
administered and what it was indicated for, whether concomitant medication targeting AUD 
was administered, and whether detoxification was performed before initiation of 
antidepressant study medication. We used a mixed-effects meta-regression to examine the 





Selection of Studies 
Figure 1 depicts our procedure for selection of studies in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.44 Our 
initial search identified 75 citations, of which 16 clinical trials were eligible for inclusion in 
this meta-analysis. 
Table 1 describes the characteristics of the 18 distinct trial arms from 16 trials 
included in this systematic review and meta-analysis, involving 1,318 participants.29, 38, 45-58 
Ten trials examined SSRI medications, 3 trials examined TCA medications, and 5 studies 
were of other antidepressants including mirtazapine, nefazodone, mianserin, and viloxazine. 
Either MDD or chronic dysthymic disorder was an indication for antidepressant treatment in 
each study. In 7 trials, subjects participated in a detoxification period prior to the initiation of 
antidepressant therapy. In 12 trials, participants received concomitant psychotherapy, in 
addition to treatment with the study medication. Concomitant psychotherapy targeted alcohol 
use in 9 studies and additionally depression in 4 studies. Three trials utilized concomitant 
pharmacotherapy, such as naltrexone, to target alcohol use. Eighteen trial arms reported 
depression outcomes as continuous symptom improvement, while 12 trial arms included 
response data in terms of depressive symptoms. The majority of included studies reported 
depression outcomes with the Hamilton Rating Scale for Depression (HAM-D). However, the 
Beck Depression Inventory (BDI), the Montgomery-Asberg Depression Rating Scale 
(MADRS), and the Lehmann-Rockliff Depression Rating Scale were utilized by one study 
each. One trial59 met our inclusion criteria, but did not contribute usable data to our study.  
Table 2 examines the risk of bias in each included trial.   
 
INSERT FIGURE 1 OF AIM 1 HERE 
INSERT TABLE 1 AND 2 OF AIM 1 HERE 
 
Depression Severity 
In participants with AUD, antidepressant medications significantly decreased 
depression severity, as compared with placebo (Standardized Mean Difference 
(SMD)=0.33±0.10 (95% Confidence Interval (CI): 0.14-0.51, k=18, z=3.4, p=0.001). There 
was significant heterogeneity between studies (χ2=42.3, df=17, p=0.001, I2=59.8%). Figure 
2A depicts the effects of antidepressant use compared with placebo on depression severity 
overall and stratified by medication type. Compared with placebo, antidepressant types did 
not demonstrate significant differences in reduction of depression severity, when trials were 
stratified by medication type (Test for subgroup differences χ2=2.15, df=2, p=0.34). Selective 
Serotonin Reuptake Inhibitors (SSRIs) (SMD=0.22±0.12 (95% CI: -0.01-0.46, k=10, z=1.9, 
p=0.06), Tricyclic Antidepressants (TCAs) (SMD=0.51±0.19 (95% CI: 0.15-0.88, k=3, 
z=2.7, p=0.006), and other antidepressants (SMD=0.51±0.30 (95% CI: -0.07-1.09, k=5, 
z=1.7, p=0.084) demonstrated similar improvements in depression severity compared with 
placebo. Figure 3A demonstrates funnel plot asymmetry suggestive of publication bias 
(Egger’s test p=0.015). 
 
INSERT FIGURES 2 AND 3 OF AIM 1 HERE 
 
In stratified subgroup analysis, trials in which subjects participated in a detoxification 
period prior to initiating antidepressant treatment (SMD=0.54±0.17 (95% CI: 0.20-0.88, k=7, 
z=3.1, p=0.002) demonstrated a similar measured benefit (Test for subgroup differences 
χ2=2.7, df=1, p=0.10) of antidepressant treatment compared with trials in which a 
detoxification period did not occur prior to initiation of an antidepressant medication 
(SMD=0.20±0.12 (95% CI: -0.03-0.42, k=11, z=1.7, p=0.09).  
Figure 4A depicts the effect of antidepressant treatment relative to placebo, stratified 
by whether or not participants received concomitant psychotherapy during the course of 
antidepressant treatment. In stratified subgroup analysis, trials in which participants did not 
receive concomitant psychotherapy (SMD=0.90±0.25 (95% CI: 0.42-1.39, k=6, z=3.66, 
p<0.001) demonstrated a significantly greater measured benefit of antidepressant treatment, 
compared with placebo, than in trials in which participants received concomitant 
psychotherapy (SMD=0.10±0.07 (95% CI: -0.03-0.23, k=12, z=1.46, p=0.15; Test for 
subgroup differences χ2=9.9, df=1, p=0.002). The measured benefit of antidepressant 
treatment, compared with placebo, was not significantly different when studies were stratified 
by whether participants did (SMD=0.24±0.13 (95% CI: -0.02-0.49, k=4, z=1.81, p=0.07) or 
did not (SMD=0.38±0.13 (95% CI: 0.12-0.63, k=14, z=2.85, p=0.004) receive psychotherapy 
for depression (Test for subgroup differences χ2=0.58, df=1, p=0.45). The measured benefit 
of antidepressant treatment was significantly different when studies were stratified by 
whether participants did (SMD=0.12±0.09 (95% CI:-0.05-0.30, k=9, z=1.37, p=0.17) or did 
not (SMD=0.57±0.18 (95% CI: 0.21-0.93, k=9, z=3.07, p=0.002) receive psychotherapy for 
alcohol use (Test for subgroup differences χ2=4.7, df=1, p=0.03). There was a significant 
difference in the measured benefit of antidepressant medications based on whether trials used 
concomitant pharmacotherapy, such as naltrexone, for alcohol use disorder (Test for 
subgroup differences χ2=5.1, df=1, p=0.024). Our analysis demonstrated a smaller measured 
benefit of antidepressant treatment when trials were stratified by whether concomitant 
pharmacotherapy was initiated to target alcohol use (SMD=-0.00±0.13 (95% CI: -0.26-0.26, 
k=3, z=-0.0, p=0.99) compared with when it was not initiated (SMD=0.40±0.12 (95% CI: 
0.17-0.63, k=15, z=3.4, p=0.001) in the trial. 
 
INSERT FIGURE 4 OF AIM 1 HERE 
 
In meta-regression, participant age (β=-0.02±0.05, 95% CI: -0.11-0.08, k=16, z=-0.32, 
p=0.75) and duration of antidepressant treatment (β=0.001±0.02, 95% CI: -0.045-0.048, 
k=16, z=0.06, p=0.96) were not associated with a measured reduction in depression severity 
following treatment with antidepressants vs. placebo. 
 
Depression Response Rate 
Participants with AUD demonstrated a significantly greater likelihood of response to 
antidepressant medications than they did to placebo (Risk ratio (RR)=1.30 (95% Confidence 
Interval (CI): 1.07-1.58, k=12, z=2.6, p=0.009). There was significant heterogeneity between 
studies (χ2=33.3, df=11, p<0.001, I2=67%). Figure 2B depicts the response to antidepressant 
use compared with placebo overall and stratified by medication type. Compared with 
placebo, antidepressant types did not demonstrate a significant difference in response, when 
trials were stratified by medication type. However, there was a trend toward marginally 
increased response to TCAs (RR=1.97 (95% CI: 1.32-2.96, k=3, z=3.3, p=0.001), as opposed 
to SSRIs (RR=1.14 (95% CI: 0.91-1.43, k=7, z=1.1, p=0.27) and other antidepressants 
(RR=1.36 (95% CI: 0.29-6.35, k=2, z=0.39, p=0.7), when compared with placebo (Test for 
subgroup differences χ2=5.4, df=2, p=0.07). Figure 3B demonstrates funnel plot asymmetry 
suggestive of publication bias, despite lack of evidence of publication bias by Egger’s test 
(Egger’s test p=0.12). 
In stratified subgroup analysis, trials in which subjects participated in a detoxification 
period prior to initiating antidepressant treatment (RR=2.77 (95% CI: 1.12-6.84, k=6, z=2.2, 
p=0.028) demonstrated a similar likelihood of response to antidepressant treatment compared 
with trials in which a detoxification period did not occur prior to initiation of an 
antidepressant medication (RR=1.47 (95% CI: 0.71-3.02, k=6, z=1.0, p=0.30); Test for 
subgroup differences χ2=1.15, df=1, p=0.28). 
Figure 4B depicts the response to antidepressant treatment compared with placebo, 
stratified by whether or not participants received concomitant psychotherapy during the 
course of antidepressant treatment. In stratified subgroup analysis, trials in which participants 
did not receive concomitant psychotherapy (RR=1.94 (95% CI: 1.17-3.23, k=4, z=2.6, 
p=0.01) demonstrated a similar likelihood of response to antidepressant treatment vs. 
placebo, compared with trials in which participants received concomitant psychotherapy 
(RR=1.13 (95% CI: 0.89-1.43, k=8, z=1.0, p=0.31). There was, however, a trend toward 
marginally increased response to antidepressants vs. placebo among patients who did not 
receive concomitant psychotherapy (Test for subgroup differences χ2=3.6, df=1, p=0.06). 
The likelihood of response to antidepressant treatment, compared with placebo, was not 
significantly different when studies were stratified by whether participants did (RR=1.22 
(95% CI: 0.95-1.56, k=4, z=1.54, p=0.12) or did not (RR=1.36 (95% CI: 0.95-1.94, k=8, 
z=1.68, p=0.09) receive psychotherapy for depression (Test for subgroup differences 
χ2=0.24, df=1, p=0.62) and also when they were stratified by whether participants did 
(RR=1.20 (95% CI:0.95-1.51, k=6, z=1.50, p=0.13) or did not (RR=1.47 (95% CI: 0.97-2.23, 
k=6, z=1.80, p=0.07) receive psychotherapy for alcohol use (Test for subgroup differences 
χ2=0.71, df=1, p=0.40). Similarly, there was no statistically significant difference in the 
likelihood of response to antidepressant treatment when studies were stratified by whether 
concomitant pharmacotherapy was initiated to target alcohol use (RR=1.00 (95% CI: 0.55-
1.80, k=2, z=0.0, p=0.99) or was not (RR=1.37 (95% CI: 1.05-1.79, k=10, z=2.3, p=0.02) in 
the trial (Test for subgroup differences χ2=0.93, df=1, p=0.34). 
In meta-regression, participant age (β=-0.039, 95% CI: -0.15-0.07, k=10, z=-0.73, 
p=0.47) and duration of antidepressant treatment (β=0.019, 95% CI: -0.03-0.07, k=10, 
z=0.77, p=0.44) were not associated with differences in the likelihood of depression response 












Aim 2: Effect of Antidepressants on Alcohol Consumption Outcomes 
Methods: 
Literature Search 
We aimed to identify all randomized placebo-controlled clinical trials of 
antidepressants that reported alcohol consumption outcomes, regardless of the indication for 
antidepressant use. Literature search was conducted using Ovid MEDLINE (1946 to 
September 23, 2016) and the Cochrane Central Register of Controlled Trials (Issue 8, August 
2016) with no language restrictions. Search terms used included a combination of alcohol use 
disorder, alcohol dependence, or alcoholism; and antidepressive agents, serotonin uptake 
inhibitors, serotonin and noradrenaline reuptake inhibitors, dopamine uptake inhibitors, 
bupropion, mirtazapine, fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, 
escitalopram, venlafaxine, desvenlafaxine, duloxetine, desipramine, imipramine, nefazodone, 
or viloxazine. Results were then limited to clinical trials. We obtained the primary articles 
associated with conference abstracts and secondary analyses resulting from our literature 
search where possible and attempted to identify additional studies via review of references 
and through consultation with two experts familiar with the published literature in this field. 
 
Study Selection  
Following removal of duplicates, abstracts were independently screened by two 
authors (JD and BA) for full-text review according to the follow inclusion criteria: 1) 
randomized placebo-controlled clinical trial, 2) of an antidepressant medication for any 
indication, 3) with alcohol consumption outcomes reported. Following this screening, full 
text articles were then reviewed by the same two authors, according to the same inclusion 
criteria. Disagreements in both screening and full text review phases were resolved by 
consensus agreement. We excluded articles conducted in an inpatient or human lab setting, 
and those conducted with adolescents. We also excluded studies with concomitant use of 
naltrexone in the treatment and placebo arms, due to evidence in previous literature of the 
confounding effects of this medication on alcohol consumption outcomes.38 Prior to data 
analysis, we also decided to exclude studies of first-generation antidepressants given their 
limited use in modern clinical practice and that few trials exist, and the fact that we had a 




Data was extracted onto specially designed Microsoft Excel spreadsheets. 
Background data extracted from the identified trials included: bibliographic information; 
indication for the trial; antidepressant medication studied; maximum medication dose; 
duration of study; concomitant psychosocial interventions; age and gender of subjects; 
moderators of early-onset alcohol use disorder, family history, or genotype; number of 
participants (n) in intention-to-treat sample and of those completing the trial; and whether or 
not participants were required to stop drinking prior to the start of the study. Alcohol 
consumption outcome measures that were extracted included: number of drinks (drinks per 
drinking day, average drinks per day, or percent change of either of these variables), number 
or proportion of drinking days, number or proportion of hazardous drinking days, and number 
of abstinent subjects throughout or at the end of the study. Depression and anxiety outcomes 
were also extracted, where available. If trial outcomes were only reported in graphical form, a 
graph digitizer program called GetData39 was used to extract the data. Studies that reported 
data of multiple treatment arms or by moderator subtype only were treated as separate studies 
for each study moderator, when no aggregate data was available. In long-term studies, where 
data was reported at multiple time points, only data closest to a 12-week follow-up period 
was extracted, in order to maintain consistency with other included studies. 
 
Statistical Analysis 
Statistical analysis was performed using Comprehensive Meta-Analysis (version 
3.0).60 Given the variation of alcohol consumption outcomes reported in the included studies 
for continuous outcomes -- number of drinking days, number of hazardous drinking days and 
drinks per day, standardized mean difference was chosen as the summary statistic. For 
abstinence, a dichotomous outcome, risk ratio was utilized as the summary statistic. Given 
the heterogeneity in medications, trial design and study outcomes, we chose to use a random-
effects model.  Heterogeneity was assessed by calculating the Q statistic41, and the I2, a 
transformation of Q that indicates the proportion of observed variance that can be attributed 
to heterogeneity, rather than sampling error.42 Publication bias was assessed by creating 
funnel plots for the outcome measures by plotting the effect size against standard error for 
each included trial. In addition, publication bias was statistically tested by the Egger test.43 
We conducted stratified subgroup analyses to examine the effects of type of antidepressant 
medication (SSRI, SNRI vs other), indication for antidepressant treatment (depression vs. 
other) and whether detoxification was performed before initiation of the antidepressant study 








Selection of Studies 
Figure 1 depicts our procedure for selection of studies in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines.44 Our initial search identified 354 citations, of which 94 were reviewed in full-text 
for eligibility. Of the 94 studies eligible for review, 18 were found to be secondary analyses 
or otherwise duplicate reports of trials already assessed, 39 did not meet the inclusion criteria 
outlined above, and 11 met the exclusion criteria above. Reasons for not meeting inclusion 
criteria included the study not being a randomized placebo-controlled clinical trial (21 
studies), not being a study of an antidepressant (2 studies), or not reporting results of one of 
the alcohol consumption outcomes outlined above (16 studies). We excluded studies of 
adolescents (2 studies) and those that included naltrexone in both the treatment and placebo 
arms (4 studies). After the literature search, but prior to data analysis we also excluded trials 
of first-generation antidepressants (5 studies), as discussed above. All categories are 
exclusive of each other, with excluded studies categorized per the order presented above. 
 
INSERT FIGURE 1 OF AIM 2 HERE 
 
Table 1 describes the characteristics of the 26 studies included in this systematic 
review, involving 2,771 participants.29, 32, 33, 48-50, 55, 57, 60-77 Seventeen studies were of an 
SSRI, 1 study was of an SNRI, and 8 studies were of other third-generation antidepressants 
including bupropion, mirtazapine, and nefazodone. Seven of the 26 included studies had a 
depressive disorder as a primary indication for the study and were limited to the medications: 
fluoxetine, sertraline, mirtazapine, and nefazodone. Participants were abstinent from alcohol 
at the start of the trial (antidepressant initiation) in 15 of the 26 studies, and all but 5 studies 
included some type of concomitant psychotherapy. There was considerable variation in which 
alcohol consumption outcomes were reported, with the most common outcome being 
proportion of drinking days per month (DD), followed by drinks per drinking day (DDD) or 
average drinks per day (ADD) when DDD was not available, abstinence either at the study’s 
end or throughout the study, and finally proportion of hazardous drinking days per month 
(HDD). Only 3 studies included all 4 outcome variables of interest, while 35% of the studies 
included at least 3 of these outcomes. 
 
INSERT TABLE 1 OF AIM 2 HERE 
 
Drinking Days 
Overall, the use of antidepressant medications was not associated with any difference 
in the number of drinking days compared to placebo (standardized mean difference (SMD) 
=0.05 ± 0.06 (95% Confidence Interval (CI): 0.06-0.16, k=24, z=0.9, p=0.39). There was 
modest but statistically significant heterogeneity between studies (Q-statistic=40.0, df=23, 
p=0.02, I2=26%).  Figure 2A depicts the effects of antidepressant use compared to placebo on 
number of drinking days stratified by medication type. SSRI, SNRI and other antidepressant 
medications did not have significantly different effects on number of drinking days compared 
to placebo (Test for subgroup differences χ2=2.1, df=2, p=0.34). Figure 3A depicts the 
effects of antidepressant use compared to placebo on number of drinking days stratified by 
diagnostic indication (depression vs. other). Trials prescribing antidepressants to treat 
depression (SMD=-0.28 ± 0.12 (95% CI:-0.52-0.04, k=5, z=-2.3, p=0.02) demonstrated a 
greater reduction in number of drinking days with antidepressant treatment compared to those 
trials which utilized antidepressants for other indications (SMD=0.14 ± 0.07 (95% CI:0.01-
0.27, k=19, z=2.2, p=0.03; test for subgroup differences χ2=9.3, df=1, p=0.002). 
Antidepressants had no effect on number of drinking days regardless of whether trials started 
subjects on an antidepressant medication after a detoxication period or not (test for subgroup 
differences χ2=0.2, df=1, p=0.87). Antidepressant agents, compared to placebo, had no effect 
on number of drinking days in trials with a detoxification period (SMD=-0.06 ± 0.09 (95% 
CI:-0.11-0.23, k=15, z=-0.7, p=0.51) or without a detoxification period prior to initiating 
antidepressant treatment (SMD=-0.04 ± 0.11 (95% CI:-0.18-0.25, k=9, z=-0.3, p=0.75). 
There was no funnel plot asymmetry suggestive of publication bias and the Egger’s test was 
also not statistically significant (p=0.11). 
 
INSERT FIGURE 2 OF AIM 2 HERE 
INSERT FIGURE 3 OF AIM 2 HERE 
 
Drinks Per Day 
Overall, the use of antidepressant medications was not associated with any difference 
in the number of drinks per day compared to placebo (SMD=0.07 ± 0.06 (95% CI: -0.04-
0.18, k=17, z=1.27, p=0.21). There was modest but statistically significant heterogeneity 
between studies (Q-statistic=24.8, df= 16, I2=36%). Figure 2B depicts the effects of 
antidepressant use compared to placebo on number of drinks per day stratified by medication 
type. SSRI, SNRI and other antidepressant medications did not have significantly different 
effects on number of drinks per day compared to placebo (test for subgroup differences χ 2= 
0.15, df=1, p=0.69). Figure 3B depicts the effects of antidepressant use compared to placebo 
on number of drinks per day stratified by diagnostic indication (depression vs. other). Trials 
prescribing antidepressants to treat depression (SMD=-0.45 ± 0.15 (95% CI: -074-(-)0.16, 
k=4, z=-3.02, p=0.003) demonstrated a greater reduction in number of drinks per day with 
antidepressant treatment compared to those trials which utilized antidepressants for other 
indications (SMD=0.16 ± 0.06 (95% CI: 0.04-0.28, k=13, z=2.61, p=.009; test for subgroup 
differences χ2=14.3, df=1, p<0.001). Antidepressants had no effect on drinks per day 
regardless of whether trials started subjects on an antidepressant medication after a 
detoxification period or not (test for subgroup differences χ2=0.008, df=1, p=0.93). 
Antidepressants agents, compared to placebo, had no effect on drinks per day in trials with a 
detoxification period (SMD=0.04 ± 0.11 (95% CI:-0.19-0.26, k=8, z=0.34, p=0.74) or 
without a detoxification period prior to initiating antidepressant treatment (SMD=0.02 ± 0.10 
(95% CI: -0.17-0.22, k=9, z=0.24, p=0.81). There was no funnel plot asymmetry suggestive 
of publication bias and the Egger’s test was also not statistically significant (p=0.05). 
 
Hazardous Drinking Days 
Overall, the use of antidepressant medications was not associated with any difference 
in number of hazardous drinking days compared to placebo (SMD=0.17± (95% CI: -0.08-
0.41, k=14, z=1.35, p=0.18). There was statistically significant heterogeneity between studies 
(Q-statistic=47.4, df=13, p<0.001, I2=73%). Figure 2C depicts the effects of antidepressant 
use compared to placebo on hazardous drinking days stratified by medication type. SSRI, 
SNRI and other antidepressant medications did not have significantly different effects on 
number of hazardous drinking days compared to placebo (test for subgroup differences χ 
2=1.0, df=2, p=0.61). Figure 3C depicts the effects of antidepressant use compared to placebo 
on hazardous drinking days stratified by diagnostic indication (depression vs. other). There 
was no significant difference in hazardous drinking days when trials were stratified by 
diagnostic indication (test for subgroup differences I2=3.0, df=1, p=0.08). Trials prescribing 
antidepressants to treat depression (SMD=-0.52 ± 0.42 (95% CI:-1.34-0.29, k=3, z=-1.26, 
p=0.21) demonstrated a marginally greater, but not statistically significant, reduction in 
hazardous drinking days with antidepressant treatment compared to those trials which utilized 
antidepressants for other indications (SMD=0.23 ± 0.13 (95% CI:-0.02-0.29, k=11, z=1.8, 
p=0.07). Antidepressants had no effect on number of hazardous drinking days regardless of 
whether trials started subjects on an antidepressant medication after a detoxification period or 
not (test for subgroup differences I2=0.29, df=1, p=0.59). Antidepressant agents, compared to 
placebo, had no effect on number of hazardous drinking days in trials with a detoxification 
period (SMD=0.15 ±0.17 (95% CI:-0.19-0.49, k=10, z=0.85, p=0.40) or without a 
detoxification period prior to initiation of antidepressant treatment (SMD=-0.07 ± 0.35 (95% 
CI:-0.77-0.63, k=4, z=-0.19, p=0.85). There was no funnel plot asymmetry suggestive of 
publication bias and the Egger’s test was also not statistically significant (p=0.94).   
 
Abstinence 
Overall, the use of antidepressant medications was not associated with any difference 
in abstinence rates compared to placebo (risk ratio (RR)=0.99 (95% CI: 0.91-1.08, k=19, z=-
0.3, p=0.77). There was no significant heterogeneity between studies (Q-statistic=19.9, 
df=18, p=0.34, I2=9%). Figure 2D depicts the effects of antidepressant use compared to 
placebo on abstinence stratified by medication type. SSRI, SNRI and other antidepressant 
medications did not have significantly different effects on abstinence compared to placebo 
(test for subgroup differences χ2=0.7, df=2, p=0.69). Figure 3D depicts the effects of 
antidepressant use compared to placebo on abstinence rates stratified by diagnostic indication 
(depression vs. other). Both trials prescribing antidepressants to treat depression (RR=1.01 
(95% CI: 0.91-1.13, k=19, z=-0.29, p=0.77) and other indications (RR=0.95 (95% CI: 0.91-
1.13, k=19, z=-0.29, p=0.77) suggested no effect on abstinence rates (test for subgroup 
differences χ2=0.5, df=1, p=0.49). Antidepressant agents, compared to placebo, similarly had 
no effect on abstinence rates in trials with a detoxification period (RR=0.95 (95% CI: 0.84-
1.08, k=13, z=-0.8, p=0.42) or without a detoxification period prior to initiation of 
antidepressant treatment (RR=1.01 (95% CI: 0.88-1.56, k=6, z=0.17, p=0.87). There was no 
funnel plot asymmetry suggestive of publication bias and the Egger’s test was also not 




Our systematic review provides evidence in Aim 1 that antidepressant medications 
significantly decrease depression severity, as compared with placebo, in populations with 
comorbid MDD and AUD. The magnitude of depressive symptom improvement, using 
antidepressants, in patients with MDD and comorbid AUD seems fairly comparable to the 
benefits observed in patients with MDD in general.11, 12 Further analysis suggests that the 
measured benefit of antidepressant agents was greater in trials that did not give concomitant 
pharmacotherapy for AUD or psychotherapy. Additionally, we did not demonstrate any 
difference in the measured efficacy of antidepressant agents compared with placebo based on 
medication class. TCAs and SSRIs showed similar benefits when compared with placebo in 
subjects with MDD and comorbid AUD. 
Our meta-analysis suggests that antidepressant agents can be effective in treating 
patients with MDD and comorbid AUD. Stratified subgroup analysis suggests that there is no 
significant difference in the measured efficacy of different classes of antidepressants (e.g. 
TCAs vs. SSRIs). The clinically significant findings of our study suggest that depressive 
symptoms warrant similar pharmacological treatment in patients with comorbid AUD. That 
is, among commonly prescribed antidepressants, there is little evidence for differences in 
efficacy, and choice of agent should be based on tolerability, side-effect profile, and potential 
interactions with other medications or addictive substances. 
Our systematic review also demonstrated a decrease in the measured benefit of 
antidepressant agents compared with placebo when other interventions, such as 
pharmacological treatments for AUD or psychotherapy, were started concomitantly. This 
result is not surprising, given that concomitant psychotherapy and/or pharmacotherapy for 
AUD likely produce a greater variation in treatment response (especially in the placebo 
group) and also may differentially lead to greater improvement in depressive symptoms in the 
placebo group, since subjects randomized to antidepressants may experience a significant 
improvement, regardless of whether they receive additional therapy, while subjects 
randomized to placebo may exhibit greater improvement with additional therapy. Our 
findings regarding psychotherapy as a moderator are consistent with two previous systematic 
reviews,21, 37 but are inconsistent with one meta-analysis that showed no moderating effects 
of psychotherapy.13 We suggest that future trials studying this dual diagnosis population 
might consider minimizing concomitant interventions, such as pharmacotherapy for alcohol 
use or psychotherapy, in order to more directly study the effect of antidepressants in this 
population. However, clinically, it seems like providing rigorous pharmacotherapy for AUD 
and/or psychotherapy might also lead to significant improvements in depressive symptoms. 
This treatment approach might be particularly useful for patients who have a history of non-
responsiveness to antidepressants or are averse to taking them.   
We were not able to demonstrate any significant moderating effects when studies 
were stratified by whether comorbid AUD and MDD subjects participated in a detoxification 
period prior to the initiation of an antidepressant medication. Nevertheless, the benefit of 
antidepressant treatment in patients who underwent a detoxification period prior to starting an 
antidepressant showed a greater benefit compared with patients who did not undergo 
detoxification. This difference in effect size was, however, not statistically significant. Future 
studies may want to examine how the timing of antidepressant initiation in relation to alcohol 
detoxification alters the efficacy of antidepressants in patients with this comorbidity. 
The systematic review conducted in Aim 1 has several limitations that may limit 
generalizability. There are fairly few studies examining the benefits of antidepressants in 
subjects with comorbid AUD and MDD. The scarcity of trials limited our power to examine 
potential moderators. Furthermore, moderators of interest were often correlated across 
studies, e.g. TCA trials tended to be conducted in earlier years, so they were less likely to 
involve concomitant psychotherapy or pharmacological treatment for AUD. The included 
studies also suggest possible publication bias, as there was a large degree of heterogeneity 
across the included trials. While we were able to identify several sources of heterogeneity 
within this meta-analysis, there are likely several differences between trials and, thus, 
multiple potential sources of heterogeneity that were not measured. These include treatment 
adherence, as well as the length and severity of the current major depressive episode. In 
addition, this meta-analysis did not include any trials that utilized the commonly prescribed 
medication classes of Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) or bupropion. 
Taken together, our findings in Aim 1 suggest that antidepressant treatment is 
associated with a decrease in depression severity in patients with comorbid AUD and MDD, 
regardless of the class of antidepressant studied. This improvement in depressive symptoms 
seems comparable to the effects observed in MDD patients without comorbid AUD. Trials 
without concomitant pharmacotherapy targeting AUD or without psychotherapy 
demonstrated a greater measured benefit of antidepressant treatment. In summary, there 
appears to be insufficient evidence to suggest that depression should be treated differently 
pharmacologically in patients with comorbid AUD, and choice of pharmacological agent 
should be based on tolerability, side-effect profile, and potential interactions with other 
medications or addictive substances. Given the state of the current evidence base, it would 
seem reasonable for clinicians to extrapolate the treatment recommendations for Major 
Depression in general to subjects who also have comorbid AUD. In addition, effectively 




The systematic review conducted as part of Aim 2 is the first meta-analysis to 
demonstrate that second and third-generation antidepressants, regardless of class, have 
neither a positive nor negative effect on alcohol drinking outcomes in a broad selection of 
trials studying these medications for any indication. In the case of alcohol related outcomes, 
however, psychiatric diagnosis matters. In an important update to older meta-analyses,21, 22 
our results do show that these newer antidepressants have statistically significant efficacy for 
decreasing drinking days and drinks per day in the cohort of subjects with alcohol 
dependence and comorbid depression. These findings, therefore, suggest that any reduction in 
alcohol intake when an antidepressant is prescribed for depression may be mediated by 
improvement in depressive symptoms. Alternatively, it is possible that antidepressants do 
directly reduce alcohol consumption in a subset of patients with comorbid depression and 
alcohol use disorder. This may be due to the shared etiologies of these two conditions, upon 
which antidepressants from different classes act. By contrast, our meta-analysis provided 
some evidence that the use of antidepressants may worsen some drinking related outcomes 
when these medications are prescribed for indications other than depression. The findings of 
our meta-analysis do not support the use of any antidepressant medication class over another, 
as they relate to alcohol consumption outcomes, among a wide cross-section of patients. 
Nonetheless, there is some evidence that antidepressants are associated with an increase in 
maladaptive drinking behavior when used for indications other than depression, which could 
potentially be explained by a subset of patients who respond differently to antidepressants 
than the general population.  
Strengths of this systematic review and meta-analysis conducted as part of Aim 2 
include using broad inclusion criteria for studies that report on alcohol consumption 
outcomes, regardless of the original indication for these medications. We were further able to 
maintain a broad optic by examining multiple alcohol consumption outcomes, whereas 
merely selecting one outcome of interest would have excluded 31-65% of our included 
articles, depending on the outcome chosen. Moreover, we analyzed these trials by both 
medication class and diagnostic indication to delineate the extent to which these moderators 
affect outcomes. Aim 2 does have important limitations that may limit generalizability. Most 
notably, the wide variety of alcohol consumption outcomes reported throughout the literature 
affected our ability to synthesize the data. Because most studies did not include all outcomes 
of interest, each meta-analysis reported herein contains a different combination of studies. 
Additionally, we included a wide variety of trials studying different medication indications, 
which necessarily increased heterogeneity. 
Given the paucity of data available for antidepressants in the subtypes of subjects 
discussed above, we believe future research in this field should consider age of onset as a 
moderator of effect for alcohol consumption outcomes. More research is also needed 
specifically comparing SSRIs to third-generation antidepressants with other mechanisms of 
action, such as mirtazapine or bupropion, particularly in a population of subjects with early-







Tables and Figures for Aim 1 

























for Alcohol Use 
Adamson et al., 201545 citalopram SSRI 60 12 138 43.6 40.6 Yes 
MET and  
supportive 
therapy 
No Yes No Yes 
Krupitsky et al., 201246 escitalopram SSRI 10 12 60 42.4 78.3 No none Yes No No No 
Roy et al., 199847 sertraline SSRI 100 6 36 40.9 91.7 No none Yes No No No 
Pettinati et al., 200129 sertraline SSRI 169.5 14 100 44.6 52 Yes 
12 step  
facilitation 
No Yes No No 
Gual et al., 200348 sertraline SSRI 150 24 83 47 53 No none Yes No No No 
Moak et al., 200349 sertraline SSRI 200 12 82 41 61 Yes CBT Yes Yes Yes No 
Kranzler et al., 2006 – 
High dep50 
sertraline SSRI 200 10 189 42.7 63.8 Yes 
supportive  
therapy 
No No No No 
Kranzler et al., 2006 – 
Low dep50 
sertraline SSRI 200 10 139 42.7 63.8 Yes 
supportive  
therapy 
No No No No 
Pettinati et al., 2010 – 
with naltrexone38 
sertraline SSRI 200 14 91 43.1 62.6 Yes CBT No Yes Yes Yes 
Pettinati et al., 2010 - 
without naltrexone38 
sertraline SSRI 200 14 79 43.1 62 Yes CBT No Yes Yes No 
Mason et al., 199651 desipramine TCA 300 24 28 38.3 86.1 No none Yes No No No 
Butterworth et al., 197152 imipramine TCA 200 3 40 
 
100 No none Yes No No No 






No Yes No No 
McLean et al., 198654 mianserin other 120 4 35 36.5 68.8 Yes 
group and  
individual 
therapy 
Yes Yes No Yes 
Cornelius et al., 201655 mirtazapine other 30 12 14 41.3 71 Yes MET No Yes No No 
Roy-Byrne et al., 200056 nefazodone other 500 12 64 40.2 45.3 Yes 
CBT and  
psychoed 
groups 
No Yes Yes No 
Hernandez-Avila et al., 
200457 
nefazodone other 600 10 41 42.9 48.8 Yes 
supportive  
therapy 
No No No No 
Altamura et al., 199058 viloxazine other 400 12 30 44.53 80 No none No No No No 
Abbreviations: SSRI = Selective Serotonin Reuptake Inhibitor, TCA = Tricyclic Antidepressant, CBT = 
Cognitive Behavioral Therapy, MET = Motivational Enhancement Therapy, High dep = HAM-D>=17, 















































































Adamson et al., 201545 5               + + + ? + ? 
Krupitsky et al., 2012 5 + + + + - - 
Roy et al., 199847 4 ? ? ? ? ? + 
Pettinati et al., 200129 4 + ? ? ? + + 
Gual et al., 200348 5 + ? + ? + + 
Moak et al., 200349 4 + ? ? ? + + 
Kranzler et al., 200650 4 + ? ? ? + + 
Pettinati et al., 201038 3 + + + ? + + 
Mason et al., 199651 4 ? ? + ? - - 
Butterworth et al., 197152 3 ? ? ? ? - ? 
McGrath et al., 199653 4 ? ? - ? + - 
McLean et al., 198654 3 ? ? ? ? - - 
Cornelius et al., 201655 3 ? ? + ? + + 
Roy-Byrne et al., 200056 3 ? ? + + + + 
Hernandez-Avila et al., 200457 3 + + + ? + + 
Altamura et al., 199058 4 ? ? ? ? ? - 
 
Key:  
low risk of bias               high risk of bias unclear risk of bias      
 
 














































+ - ? 
Records identified through 
database searching 










 Additional records identified 
through other sources 
(n = 7) 
Records after duplicates removed 
(n = 75) 
Records screened 
(n = 75) 
Records excluded by title 
or abstract 
(n = 44) 
Full-text articles assessed 
for eligibility 
(n = 31) 
Full-text articles excluded 
(n = 15):  
Duplicate trial  
(n = 3) 













Participants had multiple 
substance use disorders 
(n=2) 
Studies included in 
qualitative synthesis 
(n = 16) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 16) 













































































































































Figure 4b. Forest Plot-Risk Ratio of Response Stratified by Concomitant Psychotherapy
Figure Legends for Aim 1: 
 
Figure 1: Selection of Studies. Figure 1 is a PRISMA flow diagram depicting selection of 
studies. 
 
Figure 2: Effect of antidepressants on depression outcomes-stratified by medication type.   
Figure 2A examines the effect of antidepressant agents compared with placebo on depression 
outcomes, when outcomes were analyzed using standardized mean difference. Figure 2B 
examines risk ratio of response. 
 
Figure 3: Funnel Plot. Figure 3A examines the included clinical trials for publication bias, 
when outcomes were analyzed using standardized mean difference. Figure 3B examines risk 
ratio of response. 
 
Figure 4: Effect of antidepressants on depression outcomes-stratified by concomitant 
psychotherapy. Figure 4A examines the effect of antidepressant agents compared with placebo 
on depression outcomes, when outcomes were analyzed using standardized mean difference. 




























Tables and Figures for Aim 2 
























  SSRI       




Alcohol 12 265 
(70) 
Yes MI, Group DDD, DD, 
abstinence 




Alcohol 12 99 (57) No Psychoeducat
ion 
DDD, DD 




Alcohol 12 62 
(100) 
Yes Supportive abstinence 
Janiri et al., 199663 fluoxetine 
(20) 
Alcohol 9 50 (80) Yes 12-step abstinence 






12 51 (51) Yes Supportive DDD, DD, HDD, 
abstinence 




Alcohol 4 41 
(100) 
No None DDD, DD 




Alcohol 12 28 
(100) 
Yes 12-step abstinence 




Alcohol 12 101 
(80) 
No CBT DDD, DD 
Chick et al., 200432 fluvoxamine 
(300) 
Alcohol 12 492 
(74) 
Yes None DD, abstinence 




Anxiety 16 42 (52) No None DDD, DD, HDD 
Brady et al., 200569 sertraline 
(150) 
PTSD 12 94 (54) Yes CBT ADD, HDD 




24 83 (53) Yes None DD, abstinence 
Hien et al., 201570 sertraline 
(200) 












No Supportive ADD, DD 




Alcohol 12 134 
(81) 
Yes Coping Skills DD, HDD 




12 82 (61) Yes CBT DDD, DD 




Alcohol 14 100 
(52) 
No 12-step DD, abstinence 
 SNRI       








 Other       




9 58 (84) Yes Group ADD, DD 











Alcohol 8 59 
(100) 
No None ADD 






12 14 (71) No MI DDD, DD, HDD 















10 41 (49) No Supportive DDD, DD, HDD, 
abstinence 




Alcohol 11 122 
(76) 
Yes Coping Skills ADD, DD, HDD, 
abstinence 










Abbreviations: SSRI = Selective Serotonin Reuptake Inhibitor, SNRI = Serotonin and Norepinephrine Reuptake 
Inhibitor, PTSD = Post-traumatic Stress Disorder, MI = Motivational Interviewing, CBT = Cognitive Behavioral 
Therapy, DDD = Drinks per Drinking Day, ADD = Average Drinks per Day, DD = Drinking Days, HDD = Hazardous 
Drinking Days
 46 















































Records identified through 
database searching 
(n = 446) 






























Additional records identified 
through other sources 
(n = 3) 
Records after duplicates removed 
(n = 354) 
Records screened 
(n = 354) 
Records excluded 
(n = 260) 
Full-text articles assessed 
for eligibility 
(n = 94) 
Full-text articles excluded 
(n = 68):  
• Duplicate studies (n 
= 18) 
• Not randomized, 
placebo-controlled 
trials (n=21) 
• Did not evaluate 
antidepressants of 
interest (n=7) 




• Did not examine 






Studies included in 
qualitative synthesis 
(n = 26) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 26) 
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Figure Legends for Aim 2: 
 
Figure 1: Selection of Studies. Figure 1 is a PRISMA Flow Diagram Depicting Selection of 
Studies. 
 
Figure 2: Effect of antidepressants on alcohol use outcomes stratified by medication type.   
Figure 2A examines the effects of antidepressant agents compared to placebo on drinking days, 
Figure 2B examines drinks per day, Figure 2C examines hazardous drinking days and Figure 2D 
examines abstinence. 
 
Figure 3: Effect of antidepressants on alcohol use outcomes stratified by diagnostic 
indication. Figure 3A examines the effects of antidepressant agents compared to placebo on 
drinking days, Figure 3B examines drinks per day, Figure 3C examines hazardous drinking days 
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